Cannabis Use and Nicotine Vaping Cessation Outcomes: A Secondary Analysis of a Randomized Clinical Trial.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

Cannabis use is prevalent among adolescents and young adults who vape nicotine.

It is not known if cannabis use affects nicotine vaping cessation success.

Who Took Part

The age groups tagged for this paper are teenagers, young adults and adults, both men and women.

This secondary analysis of a randomized clinical trial with youth who vaped nicotine recruited at a single site in Massachusetts from June 2022 to May 2024.

The trial included 3 groups receiving 12 weeks of varenicline treatment and placebo (both double-masked, paired with counseling), as well as single-masked referral to texting-app-based nicotine vaping cessation support (enhanced usual care [EUC]).

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

Eligible participants were aged 16 to 25 years who reported vaping nicotine regularly and did not smoke tobacco.

What Was Measured

Topics PubMed links to this paper include Vaping, Varenicline, Marijuana Use, Massachusetts, Smoking Cessation, Marijuana Abuse and Nicotine.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (JAMA network open), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.